Ipsen pays Lexicon $23m upfront for ex-US, Japan rights to PhIII drug

Ipsen of France has signed a deal with Texan firm Lexicon Pharmaceuticals for an exclusive license to commercialize telotristat etiprate outside North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon, which bags $23m upfront under the deal, retains sole rights to commercialize telotristat etiprate in those territories.

Ipsen of France has signed a deal with Texan firm Lexicon Pharmaceuticals for an exclusive license to commercialize telotristat etiprate outside North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon, which bags $23m upfront under the deal, retains sole rights to commercialize telotristat etiprate in those territories.

Lexicon could receive up to $145m in total: $23m in cash and the rest as clinical, regulatory and commercial milestone...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category